NASDAQ:CNTG Centogene (CNTG) Stock Price, News & Analysis → Look Who Fired the World’s Richest Man (From Banyan Hill Publishing) (Ad) Free CNTG Stock Alerts $0.44 +0.04 (+10.12%) (As of 05/14/2024 ET) Add Compare Share Share Today's Range$0.40▼$0.4550-Day Range$0.38▼$0.7152-Week Range$0.36▼$1.98Volume102,988 shsAverage Volume64,269 shsMarket Capitalization$11.78 millionP/E RatioN/ADividend YieldN/APrice Target$1.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Centogene alerts: Email Address Centogene MarketRank™ Stock AnalysisAnalyst Rating0.00 Rating ScoreUpside/Downside244.7% Upside$1.50 Price TargetShort InterestHealthy0.33% of Float Sold ShortDividend StrengthN/ASustainability-1.26Upright™ Environmental ScoreNews Sentiment0.46Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.46 out of 5 stars 2.0 Analyst's Opinion Amount of Analyst CoverageCentogene has received no research coverage in the past 90 days.Read more about Centogene's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.33% of the float of Centogene has been sold short.Short Interest Ratio / Days to CoverCentogene has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Centogene has recently increased by 546.77%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCentogene does not currently pay a dividend.Dividend GrowthCentogene does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCentogene has received a 70.13% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Private genetic testing services", "Non-invasive prenatal testing services", and "Private medical screening services" products. See details.Environmental SustainabilityThe Environmental Impact score for Centogene is -1.26. Previous Next 2.5 News and Social Media Coverage News SentimentCentogene has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Centogene this week, compared to 1 article on an average week.Search Interest2 people have searched for CNTG on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Centogene insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.93% of the stock of Centogene is held by insiders.Percentage Held by InstitutionsOnly 9.94% of the stock of Centogene is held by institutions.Read more about Centogene's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioCentogene has a P/B Ratio of 1.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Centogene's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceCrypto Pioneer Says: “The last crypto bull market has begun.”Right now, there’s over $6 trillion in potential investment money waiting on the sidelines. That means this crypto bull market has a lot more room to run before it comes close to being a bubble.Click here if you’d like to learn more about these five cryptos… About Centogene Stock (NASDAQ:CNTG)Centogene N.V., together with its subsidiaries, engages in the research and development of products for human genetics in Europe, the Middle East, North America, Latin America, and the Asia Pacific. It provides data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. It operates through two segments: Pharmaceutical and Diagnostics. The company provides target and drug screening, clinical development, market access and expansion, as well as CENTOGENE Biodatabank licenses and insight report services. In addition, it offers various services, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.Read More CNTG Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CNTG Stock News HeadlinesMay 14 at 8:30 AM | globenewswire.comCENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher DiseaseMay 10, 2024 | finanznachrichten.deCentogene NV: CENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse PatientsMay 10, 2024 | globenewswire.comCENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse PatientsApril 4, 2024 | investing.comCentogene faces Nasdaq delisting over share priceApril 2, 2024 | globenewswire.comCENTOGENE Receives Nasdaq Non-Compliance NoticeMarch 22, 2024 | fool.comCentogene (NASDAQ: CNTG)March 19, 2024 | globenewswire.comCENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage DisordersMarch 1, 2024 | finanznachrichten.deCentogene NV: CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRa DeficiencyFebruary 29, 2024 | it.investing.comCENTOGENE scopre la carenza del recettore alfa delle cellule pre-TFebruary 29, 2024 | globenewswire.comCENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα DeficiencyFebruary 28, 2024 | finanznachrichten.deCentogene NV: CENTOGENE Explores Strategic AlternativesFebruary 28, 2024 | finanznachrichten.deCentogene NV: CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a HearingFebruary 28, 2024 | markets.businessinsider.comCentogene Explores Strategic Alternatives, Incl. SaleFebruary 28, 2024 | markets.businessinsider.comCentogene Announces Receipt Of Nasdaq Notice Of DelistingFebruary 28, 2024 | msn.comCentogene to explores strategic alternatives, gets Nasdaq delisting notice; shares plungeFebruary 28, 2024 | globenewswire.comCENTOGENE Explores Strategic AlternativesFebruary 28, 2024 | globenewswire.comCENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a HearingJanuary 25, 2024 | finanznachrichten.deCentogene NV: CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research CollaborationJanuary 25, 2024 | finance.yahoo.comCENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research CollaborationJanuary 24, 2024 | finanznachrichten.deCentogene NV: CENTOGENE Receives French Research Tax Credit AccreditationJanuary 23, 2024 | finance.yahoo.comCENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using MultiomicsJanuary 18, 2024 | finance.yahoo.comCENTOGENE Announces Preliminary Full Year 2023 RevenueDecember 21, 2023 | morningstar.comCentogene NV Ordinary Shares CNTGDecember 13, 2023 | finanznachrichten.deCentogene NV: CENTOGENE's Frontotemporal Dementia (FTD) Genetic Study, EFRONT, Reaches Initial Patient Enrollment MilestoneDecember 13, 2023 | msn.comMotus GI, C4 Therapeutics among healthcare moversSee More Headlines Receive CNTG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Centogene and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/24/2021Today5/14/2024Next Earnings (Estimated)5/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:CNTG CUSIPN/A CIK1757097 Webwww.centogene.com Phone38180113500FaxN/AEmployees444Year FoundedN/APrice Target and Rating Average Stock Price Target$1.50 High Stock Price Target$1.50 Low Stock Price Target$1.50 Potential Upside/Downside+244.7%Consensus Rating Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$50.03 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.29 per share Price / Book1.50Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta-0.67 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMs. Kim Stratton (Age 62)CEO & Member of Management Board Comp: $933.13kMr. Jose Miguel Coego RiosCFO, Legal & IT and Member of Management BoardDr. Peter Bauer M.D. (Age 54)Chief Medical & Genomic Officer and Member of Management Board Comp: $186.41kDr. Andrin Oswald M.D. (Age 52)Ph.D., Advisor Comp: $943.96kMr. Ian RentschChief Commercial Officer & GM of PharmaKey Competitors180 Life SciencesNASDAQ:ATNFW60 Degrees PharmaceuticalsNASDAQ:SXTPWAclarionNASDAQ:ACONWAinosNASDAQ:AIMDWAlpha Tau MedicalNASDAQ:DRTSWView All CompetitorsInstitutional OwnershipPlatinum Investment Management Ltd.Sold 1,190,340 shares on 5/14/2024Ownership: 0.000%View All Institutional Transactions CNTG Stock Analysis - Frequently Asked Questions What is Centogene's stock price target for 2024? 0 equities research analysts have issued 12-month price objectives for Centogene's shares. Their CNTG share price targets range from $1.50 to $1.50. On average, they predict the company's share price to reach $1.50 in the next year. This suggests a possible upside of 244.7% from the stock's current price. View analysts price targets for CNTG or view top-rated stocks among Wall Street analysts. How have CNTG shares performed in 2024? Centogene's stock was trading at $1.20 at the start of the year. Since then, CNTG shares have decreased by 63.7% and is now trading at $0.4351. View the best growth stocks for 2024 here. When is Centogene's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024. View our CNTG earnings forecast. How were Centogene's earnings last quarter? Centogene (NASDAQ:CNTG) announced its quarterly earnings results on Wednesday, November, 24th. The company reported ($1.08) EPS for the quarter, missing analysts' consensus estimates of ($0.59) by $0.49. The firm earned $35.60 million during the quarter, compared to analyst estimates of $31.91 million. During the same period in the previous year, the company earned ($0.32) earnings per share. What other stocks do shareholders of Centogene own? Based on aggregate information from My MarketBeat watchlists, some companies that other Centogene investors own include Fulcrum Therapeutics (FULC), Advanced Micro Devices (AMD), OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Alimera Sciences (ALIM), AngloGold Ashanti (AU), Chimerix (CMRX) and Entasis Therapeutics (ETTX). When did Centogene IPO? Centogene (CNTG) raised $60 million in an initial public offering (IPO) on Thursday, November 7th 2019. The company issued 4,000,000 shares at $14.00-$16.00 per share. SVB Leerink and Evercore ISI served as the underwriters for the IPO and Baird and BTIG were co-managers. Who are Centogene's major shareholders? Centogene's stock is owned by a variety of institutional and retail investors. Top institutional investors include Platinum Investment Management Ltd. (0.00%). How do I buy shares of Centogene? Shares of CNTG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CNTG) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersDid Intel Just Dethrone Nvidia?Chaikin AnalyticsClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsCharles Payne Demystifies OptionsUnstoppable ProsperityRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe only AI company you should be looking atBehind the MarketsElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Centogene Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
